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Abstract
Background: Plague is still a public health problem in the world and is re-emerging, but no efficient vaccine is available. We
previously reported that oral inoculation of a live attenuated Yersinia pseudotuberculosis, the recent ancestor of Yersinia
pestis, provided protection against bubonic plague. However, the strain poorly protected against pneumonic plague, the
most deadly and contagious form of the disease, and was not genetically defined.
Methodology and Principal Findings: The sequenced Y. pseudotuberculosis IP32953 has been irreversibly attenuated by
deletion of genes encoding three essential virulence factors. An encapsulated Y. pseudotuberculosis was generated by
cloning the Y. pestis F1-encoding caf operon and expressing it in the attenuated strain. The new V674pF1 strain produced
the F1 capsule in vitro and in vivo. Oral inoculation of V674pF1 allowed the colonization of the gut without lesions to Peyer’s
patches and the spleen. Vaccination induced both humoral and cellular components of immunity, at the systemic (IgG and
Th1 cells) and the mucosal levels (IgA and Th17 cells). A single oral dose conferred 100% protection against a lethal
pneumonic plague challenge (336LD50 of the fully virulent Y. pestis CO92 strain) and 94% against a high challenge dose
(3,3006LD50). Both F1 and other Yersinia antigens were recognized and V674pF1 efficiently protected against a F1-negative
Y. pestis.
Conclusions and Significance: The encapsulated Y. pseudotuberculosis V674pF1 is an efficient live oral vaccine against
pneumonic plague, and could be developed for mass vaccination in tropical endemic areas to control pneumonic plague
transmission and mortality.
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Introduction
Plague, the dreadful infectious disease that caused three major
pandemics in history, is still a public health problem. Since the
1980s, an increase of cases worldwide has been observed, leading
to categorize plague as a re-emerging disease. Whereas the most
active foci of human plague are located in east-central Africa and
Madagascar [1], recent cases have also been recorded in areas
from where it had disappeared for decades, like Algeria, Libya,
Zambia and Jordan [2,3,4]. Moreover, because plague is
principally a zoonotic disease affecting rodents, the territories
where it is endemic in its animal reservoir are much more
extended than the observed human plague foci.
Plague is an acute, often fatal infection whose etiologic agent,
Yersinia pestis, is a Gram-negative bacillus with an extreme
pathogenicity. The accidental transmission of the plague bacillus
from rodents to humans by the bite of infected fleas is the most
frequent mode of human infection. From the skin, the bacteria
migrate to the draining lymph nodes, causing the bubonic form of
plague, which evolves toward septicemia and death within one
week if treatment is not rapidly started. When the bacteria reach
the lungs, an acute pneumonia develops. Patients become highly
contagious through the emission of infected aerosols that cause
primary pneumonic plague. The disease is then generally fatal
within 3 days or less. Human-to-human transmission of pneu-
monic plague favors a rapid spread of the disease in heavily
populated areas, as occurred for example recently in Madagascar
and in the Democratic Republic of Congo [5,6]. Although
antibiotherapy is currently the main tool to fight the disease, the
residual plague mortality in endemic countries remains around
10% or more. This is mainly due to the difficulty for patients from
areas far from health structures to receive the treatment on time.
An additional cause of concern is the recent identification in
Madagascar of two Y. pestis strains naturally resistant to antibiotics,
one of which was resistant to eight different antibiotics, including
those recommended for plague treatment and prophylaxis [7].
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acquisition of a widespread self-transmissible plasmid [8], the rise
of such threatening Y. pestis variants may be anticipated. Finally, Y.
pestis is also classified in the list A of pathogens with potential for
bioterrorist use established by the US Center for Disease Control
due to its pathogenicity and human-to-human transmission [9],
and the possibility that the bacteria is engineered to resist to
antibiotics for evil use cannot be excluded. In front of such a public
health risk, mass vaccination might be one of the only alternatives
to protect exposed populations. However, no safe and efficient
vaccine against plague is currently available.
The first widely used plague vaccine was the live attenuated Y.
pestis EV76 developed in Madagascar. This vaccine, that can have
severe secondary effects, is now used in only few countries such as
China or the former USSR. The licensed killed whole-cell Y. pestis
vaccine from Greer/Miles was recently discontinued because it
was reactogenic in humans and conferred only short-term
protection [10], requiring annual booster immunizations. Much
effort has been made in the recent years to develop new candidate
vaccines. The strategies followed to induce protective immunity
include the attenuation of live Y. pestis by genetic engineering, the
introduction of Y. pestis antigens in Salmonella [11] and virus vectors
[12,13], as well as the production of subunit vaccines combining
the capsular F1 antigen and the V antigen (LcrV) [14,15,16].
We recently reported that the attenuated Y. pseudotuberculosis
strain IP32680 can be used as a live oral vaccine against bubonic
plague [17]. The rationale for choosing this approach was to
combine the immunogenicity and antigenic complexity of live
vaccines with the much lower virulence of Y. pseudotuberculosis.
Indeed, Y. pestis is a clone recently emerged from Y. pseudotuber-
culosis [18], and the two species share more than 95% genetic
identity. A reason not to use Y. pestis as live vaccine is its genetic
instability, as revealed by the spontaneous genome reductions
observed for the EV76 strain, which hampered its vaccine
efficiency [19]. That risk is much lower for Y. pseudotuberculosis
because such rearrangements in Y. pestis are thought to result from
the high number of insertion sequences (IS) present in its genome
[20], and Y. pseudotuberculosis has a much lower number of IS copies
and so is genetically much more stable [20]. When given orally, Y.
pseudotuberculosis IP32680 was able to colonize the gut without
causing lesions and stimulated a protective immune response
against bubonic plague [17]. These results demonstrate the
feasibility of using a live attenuated Y. pseudotuberculosis strain as
an oral vaccine against plague. However, IP32680 is not suitable
for human use because the genetic bases of its attenuation are not
known and it does not confer high-level protection against
pneumonic plague.
The aim of the present study was to construct a genetically
engineered Y. pseudotuberculosis strain irreversibly attenuated in
virulence, and able to confer high-level protection against
pneumonic plague.
Materials and Methods
Ethics statement
Animals were housed in the Institut Pasteur animal facilities
accredited by the French Ministry of Agriculture to perform
experiments on live mice (accreditation B 75 15-01, issued on may
22nd, 2008), in appliance of the French and European regulations
on care and protection of the Laboratory Animals (EC Directive
86/609, French Law 2001-486 issued on June 6, 2001). Protocols
were approved by the veterinary staff of the Institut Pasteur animal
facility and were performed in compliance with the NIH Animal
Welfare Insurance #A5476-01 issued on 02/07/2007.
Bacterial strains, plasmids and culture conditions
The Y. pseudotuberculosis and Y. pestis isolates used in this study
and their derivatives are listed in Table 1. Bacteria were grown at
28uC on Luria-Bertani agar plates supplemented with 0.2% hemin
(LBH) for 48 h before use, and bacterial concentrations were
evaluated by spectrometry at 600 nm and plating on LBH plates.
Mutagenesis
Deletion of the caf operon was performed in Y. pestis CO92p
(Table 1) using the Short Flanking Homology (SFH) procedure
[21] with primers 812 and 814 designed to exchange a portion of
the caf locus encompassing the caf1M, caf1A and caf1 genes by a
kanamycin resistance cassette (km from plasmid pGP704N-km).
Deletion of the Y. pseudotuberculosis High Pathogenicity Island (HPI:
YPTB1585 through YPTB1602), yopK (virulence plasmid gene
PYV0040) and psaA (YPTB1334) sequences from IP32953p was
done by allelic exchange with a kanamycin (km from plasmid
pUC4K), spectinomycin (spec from plasmid pSW25) and trimeth-
oprim (dfr from plasmid pGP704N-dfr) resistance cassette,
respectively. HPI deletion was done following the Long Flanking
Homology procedure [21]. yopK and psaA genes were first deleted
individually in Y. pestis CO92p (Table 1) following the SFH
procedure [21]. Second, the genomic DNA from the resulting
deletants was used as template for PCR amplification of the
antibiotic resistance cassettes flanked by the 500 bp upstream and
downstream regions of yopK and psaA genes. The PCR products
were electroporated into Y. pseudotuberculosis IP32953DHPI
(Table 1), as described previously [21]. Recombinant colonies
were selected for antibiotic resistance and were verified by PCR
with primers located: (i) on each side of the inserted antibiotic
cassette, and (ii) within each target region (Table S1). All the
primer pairs used to generate PCR products for allelic exchange
are listed in Table S1.
Cloning of the caf operon
To clone the caf operon into pGEN-lux [22], the entire locus was
amplified with primer pair 837/838, which adds NotI and ApaI
sites at the extremities. The PCR product was ligated to the
corresponding sites in place of the lux operon. Then, the ligation
mix was electroporated into E. coli TOP10 (Invitrogen). The
pGEN-lux plasmid was chosen because it contains the hok/sok
Author Summary
Plague, among the most deadly infections of mankind’s
history, is present in Africa, Asia and America, and is
currently re-emerging, recently causing cases in areas from
where it had disappeared for decades. Pneumonic plague,
its most deadly and contagious form, is responsible for
human-to-human spreading of the infection. Vaccination
would be an effective means to control the disease, but no
efficient vaccine is currently available. Because live
vaccines are potent inducers of protective immunity, our
strategy was to use a Yersinia pseudotuberculosis, closely
related to Y. pestis but genetically more stable, to make it
suitable for use as live oral vaccine. We have developed a
genetically defined Y. pseudotuberculosis strain strongly
attenuated by deletion of virulence factors genes, which
was also induced to produce the Y. pestis F1 pseudocap-
sule. A single oral dose was harmless and provided high-
level protection against pneumonic plague. Such a
candidate vaccine offers promising perspectives to control
pneumonic plague mortality and transmission.
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partition system, both stabilizing the plasmid in the bacterial
population [23]. The presence of the plasmid with the appropriate
insert (pGEN-caf) was checked after plasmid extraction and
digestion. The pGEN-caf construct was introduced by electropo-
ration into Y. pseudotuberculosis V674 and recombinant strains
selected. The sequence of the cloned caf1 gene was verified by
sequencing.
Analysis of F1 production
To determine the presence of a capsule, bacteria in India ink [24]
were examined by phase-contrast microscopy. To quantify the
production of the F1, ELISA plates (NUNC) were coated with the
anti-F1 mAb G5-18 [25], followed by a 1% BSA blocking solution
in PBS. Serial dilutions of bacterial suspensions (10
9 to 10
4 cfu/ml)
in PBS containing 0.1% BSA were laid in the wells. The plate was
centrifuged for 10 min (1000 g) prior to incubation for 1 h at room
temperature. After 3 washes with PBS, biotinylated G5-18 anti-F1
mAb (1 mg/ml) was incubated for 1 h, followed by 30 min with
Streptavidin coupled to horseradish peroxidase (Jackson Immunor-
esearch), and colorimetric revelation using TMB (OptiEIA, BD-
biosciences), as previously described [17].
Animal infection and in vivo analyses
Mouse infections were performed in a BSL3 animal facility.
Bacterial suspensions of bacteria (200 ml in saline) were given
intragastrically to seven weeks old OF1 female mice (Charles River
France) using a curved feeding needle. To determine the 50% lethal
dose (LD50), mice (six per dose) were infected with 10 fold serial
dilutionsof bacterial suspensionsand were monitored for 3weeks.The
method of Reed and Muench was used to calculate LD50 values [26].
In vivo dissemination was examined five or fifteen days after oral
inoculation of bacteria. Peyer’s patches, spleen and feces (two fecal
pellets from the large intestine) were collected aseptically from
euthanized mice and were homogenized in sterile PBS using 3 mm
glassbeadsandanelectricmill(TissueLyserH,Qiagen).Thebacterial
load was determined by plating serial dilutions of the homogenates.
The severity of lesions caused to tissues by Y. pseudotuberculosis
strains was analyzed histologically. Animals were euthanized and
target organs were fixed with 4% buffered formaldehyde for 48 h,
embedded in paraffin, cut in 5 micrometers sections, and stained
with hematoxylin–eosin. Histological sections were read blindly
and lesions were quantified using a previously described scale [17]
ranging from 0 to 10. For immunohistological detection of the F1
antigen produced in vivo, Peyer’s patches collected 5 days after
vaccination with the V674pF1 strain (10
10 cfu) were fixed and
embedded in low-melting point paraffin (polyEthylene Glycol
distearate, Aldrich). Endogenous peroxidase activity was eliminat-
ed after deparaffinization by incubation in 0.3% hydrogen
peroxide for 30 min and non-specific binding sites was blocked
for 30 min, prior to incubation (1 h) with the biotinylated anti-F1
G5-18 mAb. As a specificity control, an irrelevant and isotype-
Table 1. Bacterial strains and plasmids used in this study.
Strain, plasmid Relevant characteristics or sequence Source
CO92 derivatives
CO92 Wild type, biotype Orientalis [59]
CO92p pKOBEG-sacB introduced into CO92 by electroporation [60]
CO92DyopK CO92p deleted of yopK This study
CO92DpsaA CO92p deleted of psaA This study
CO92Dcaf CO92p deleted of the caf operon This study
IP32953 derivatives
IP32953 Wild type, serotype I [35]
IP32953p pKOBEG-sacB introduced into IP32953 by electroporation [60]
IP32953DHPI IP32953p deleted of the HPI This study
V676 IP32953p deleted of the HPI and yopK This study
V674 IP32953p deleted of the HPI, yopK and psaA This study
V674 pF1 pGEN-caf introduced into V674 by electroporation [59]
E. coli
TOP10 F-mcrA D(mrr-hsdRMS-mcrBC)f 8 0 lacZ DM15 DlacX74 recA1 araD139 D(ara-leu)7697
galU galK rpsL (StrR) endA1 nupG
Invitrogen
TOP10(pGEN-lux) TOP10 harboring pGEN-lux [22]
TOP10(pGEN-caf) TOP10 harboring pGEN-caf This study
Plasmids
pKOBEG-sacB repA cat araC pBAD exo bet gam sacB,C m
R [21]
pUC4K Km
R Amersham
pGP704N-km Suicide vector, Amp
R,K m
R [61]
pGP704N-dfr Suicide vector, Amp
R,T m
R [62]
pSW25 oriT ccdB Spec
R [63]
pGEN-lux hok/sok parR/parM bla, luxCDEAB, Amp
R [22]
pGEN-caf the caf operon replace the lux operon in pGEN-lux This study
doi:10.1371/journal.pntd.0001528.t001
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were incubated for 1 h with HistofineH Simple Stain MAX PO
(Rabbit specific; Nichirei corp.) and peroxidase activity was
detected using 3-amino ethylcarbazole (AEC) substrate (Sigma).
Tissues counterstained with Harris’ hematoxylin were then
observed using a Nikon Eclipse microscope.
Immuno-assays
Blood from live animals was collected by puncture of the
maxillary artery with a Goldenrod lancet (Medipoint, USA). To
perform intestinal lavages, the gut section extending from the
stomach to the cecum was cut from euthanized mice and flushed
with 10 ml cold PBS containing protease inhibitors (CompleteH
from Roche plus 10 mM PMSF from Sigma). After centrifugation
(10 min at 10.000 rpm), supernatants were collected and all
samples were frozen until use. Bronchoalveolar lavages were
performed by injection of PBS containing protease inhibitors in
the cannulated trachea. To quantify IgG and IgA specific for
Yersinia antigens by ELISA, microtiter plates (NUNC) were coated
with 5 mg/ml of a sonicate of Y. pseudotuberculosis IP32953
(hereafter referred to as Y. ptb Ag.) grown at 37uC on LB agar,
as described before [17]. To quantify F1–specific IgG and IgA,
plates were coated with F1 antigen (10 mg/ml), as described
previously [25]. After blocking plates with 5% dry milk in PBS
containing 0.1% Tween 20, bacteria grown at 37uC were serially
diluted in PBS containing 0.1% BSA and were incubated in wells.
Bound antibodies were detected using horseradish peroxidase
(HRPO)–coupled rat antibodies specific for mouse IgG (Becton-
Dickinson Pharmingen) or IgA (Caltag Laboratories), and HRPO
activity was revealed using TMB substrate (OptiEIA, BD
Pharmingen). Antibody titers were calculated as the reciprocal of
the lowest sample dilution giving a signal equal to two times the
background.
Cell-mediated response in vaccinated animals
Spleens taken aseptically from euthanized animals were cut in
pieces and dissociated using cell strainers (BD Biosciences).
Erythrocytes were lyzed using Gey’s hemolytic solution [27] and
splenocytes were extensively washed with cold PBS. Cells
resuspended in RPMI 1640+Glutamax
TM (Invitrogen) supple-
mented with 5% fetal bovine serum, penicillin/streptomycin and
10 mM ß-mercaptoethanol were laid in 24 wells plates (5610
6/
well) and stimulated with either Y. ptb Ag. (5 mg/ml), the F1
antigen (5 mg/ml) or Concanavalin A (1 mg/ml; Sigma) as a
positive control. After three days, the supernatant was collected
and the cytokine content was determined using IFNc and IL-17
assays (Duosets, R&D Systems).
Evaluation of mouse protection against a challenge with
Y. pestis
The fully virulent Y. pestis strain CO92 or its non-encapsulated
derivative CO92Dcaf1 (Table 1) were grown at 28uC and
suspensions in saline containing 10
5 or 10
7 cfu (336LD50 or
3,3006LD50, respectively) were prepared. Mice vaccinated or not
28 days before were anesthetized and were infected by instillation
of 10 mlo fY. pestis suspensions in the nostrils. Animal survival was
monitored for 21 days.
Statistical analyses
The Log-rank (Mantel-Cox) test was used to compare survival
curves (protection). The non-parametric Mann-Whitney test was
used to compare lesions, weight, antibody titers and cytokines
production.
Results
Construction of an attenuated variant of Y.
pseudotuberculosis IP32953
Strain IP32953 was chosen to generate an irreversibly
attenuated Y. pseudotuberculosis strain because its genome has been
determined [20]. The HPI, encoding the Yersiniabactin iron
capture system [28], was deleted by allelic exchange, generating
IP32953DHPI (Table 1). The LD50 of IP32953DHPI (LD50
oral=6.8610
8) was 16 times higher than that of the parental
IP32953 (4.2610
7 cfu). Since more attenuation was required for a
vaccine, the chromosomal psaA gene encoding the pH 6 Ag pilus
[29]) and the virulence plasmid-borne yopK gene, encoding the
type three secretion system effector protein YopK [30], were
additionally deleted. The triple deletant (DHPI, DPsaA, DYopK)
generated, named V674, exhibited a strong virulence attenuation
(LD50.3610
9 cfu), which was comparable to that of strain
IP32680 [17]. Mice receiving 10
8 cfu of V674 presented no signs
of disease and no weight loss (Fig. S1A), whereas the parental
IP32953 induces severe signs of disease and weight loss before
death [17]. Vaccination with a single oral dose (10
8 cfu) of V674
conferred protection to 69% of mice against an intranasal
challenge with the fully virulent Y. pestis strain CO92 at a dose
lethal for naive animals (10
5 cfu=336LD50). Although this level
of protection was superior to that of IP32680 (30%; [17] it was
considered insufficient, and V674 was further modified.
Construction of the V674pF1 strain producing an F1
capsule
In order to increase the ability of the candidate vaccine strain to
induce a protective immunity against Y. pestis, V674 was further
engineered to produce the Y. pestis F1 capsule. The caf operon from
CO92, required for surface production of the F1 antigen in Y.
pestis, was cloned into the pGEN plasmid. The resulting pGEN-caf
plasmid was introduced into V674, generating V674pF1 (Table 1).
The formation of a capsule around V674pF1 bacterial cells was
observed (Fig. 1A c&d). When measured using an F1-specific
ELISA, F1 production by V674pF1 was identical to that of Y. pestis
CO92 (Fig. 1B). To determine whether the F1 capsule was
produced in vivo, immunohistological staining of F1 was performed
on sections of Peyer’s patches taken from mice having received
V674pF1 five days before. Small foci of F1-positive bacteria were
detected using an anti-F1 monoclonal antibody (Fig. 1C), while no
staining was detected when an irrelevant and isotype-matched
biotinylated mAb was used as control (data not shown). The
V674pF1 was thus able to produce the F1 capsule within mouse
tissues. To determine whether the production of F1 had an impact
on the virulence of the vaccine strain, graded doses of bacteria
were inoculated orally to mice. Mice having received V674pF1
(10
8 or 10
9 cfu) presented no signs of disease and no weight loss
(Fig. S1B) and no lethality was observed. A high dose of
2610
10 cfu also caused no lethality, revealing a very strong
attenuation of virulence.
In vivo persistence and infectivity of recombinant strains
The ability of V674pF1 to persist in the intestinal tract after oral
inoculation was examined by counting bacteria present in feces
(Fig. 2). At the vaccine dose of 10
8 cfu, amounts of V674pF1 found
at day 11 (d11) were comparable to those previously noted for the
virulent IP32953 (#10
5 cfu; [17], and were also comparable to
those found with the non-encapsulated V674, indicating that
attenuation of virulence or F1 production did not affect the ability
of V674pF1 to colonize the gut. Levels of V674pF1 were
comparable when a higher vaccine dose (10
9 cfu) was used. The
Encapsulated Y. pseudotuberculosis Plague Vaccine
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infection, although at decreasing levels as compared to d11.
To evaluate the dissemination of V674pF1 toward internal
organs, its presence in Peyer’s patches and spleen was examined
(Fig. 3A). In Peyer’s patches, amounts of V674pF1, or V674 were
similar on D5, indicating that the production of F1 did not modify
its ability to infect this lymphoid tissue. Similar loads were observed
with a higher V674pF1 dose (10
9 cfu). Ten days later (D15), lower
levels of V674pF1 were observed, indicating a progressive lessening
ofinfection,inagreementwith countsseen infeces. Because animals
infected by IP32953 died before D15, they could not be compared.
In a deep organ such as the spleen, amounts of attenuated V674pF1
or V674 found 5 days after inoculation were significantly low as
compared to IP32953, in agreement with their attenuation of
virulence (Fig. 3A). Again,neither the presence of F1 northe dose of
V674pF1used affectedthe splenicload.Tendayslater,V674pF1or
V674 were most often not detectable, showing that the attenuated
bacteria were rapidly cleared (Fig. 3A).
The potential development of lesions induced by the bacteria in
these target organs was examined. As a reference, the wild type
IP32953 at the 10
8 cfu lethal dose caused severe lesions to both the
spleen and Peyer’s patches (abscesses, necrosis), together with signs
of erosion of the flanking intestinal mucosa (scores .6/10; Fig. 3
B&C). In contrast, the same dose of V674 strain caused mainly
congestion and microhemorrhages in the spleen and liver, and
infrequent abscesses (scores ,2/10, Fig. 3 B) in all three tissues
tested. When used at a high dose of 10
9 cfu to maximally reveal
potential harmful effects, theV674pF1 strain also caused mild tissue
lesions (scores #1/10; Fig. 3 B&C) that were not significantly
different from those caused by V674, in spite of the dose difference.
In agreement with bacterial clearance, histology of the spleen and
Peyer’s patches of mice vaccinated with either attenuated strain was
normal or almost normal on Day 15 (score ,1; Fig. 3 B), showing
that tissues had healed. Altogether, our observations demonstrate
that V674pF1 inoculated orally is able to colonize the gut and to
interactwithPeyer’spatches,butfailstodisseminatetohigh levelsin
the spleen, confirming its very high attenuation.
Humoral immune response elicited by vaccination
High levels of serum IgG directed against Y. pseudotuberculosis
antigens were detected in sera from mice having received one oral
dose of V674pF1 (10
8 cfu) 21 days before but not in sera from
naive mice (Fig. 4A). Increasing the vaccine dose to 10
9 cfu did not
significantly increase IgG. Comparison with mice vaccinated with
the non-encapsulated V674 strain revealed comparable anti-
Yersinia IgG levels (Fig. 4A). High levels of IgG directed against F1
Figure 1. Strain V674pF1 produces an F1 capsule. A: Strains (a)
V674 as negative control, (b) CO92 as positive control, and (c–d)
V674pF1 in India ink observed under phase-contrast microscopy. The
capsule excludes the India ink and appears as a clear halo around
bacterial cells. B: Comparison of F1 production by V674, V674pF1 and
CO92 by ELISA. C: F1 production by V674pF1 in vivo: Peyer’s patches
were taken from animals infected orally 5 days before with 10
10 cfu of
V674pF1, and subjected to an immunohistological staining with an anti-
F1 mouse mAb, followed by a hematoxylin counterstain. An example of
a bacterial focus (brown-red color) is indicated by an arrow.
doi:10.1371/journal.pntd.0001528.g001
Figure 2. Gut colonization by Y. pseudotuberculosis mutants.
Bacteria present in the feces (2 pellets) from mice orally vaccinated with
strains V674pF1 and V674 at the indicated doses (cfu) were counted
eleven and twenty days after. Shown are individual values from 4 to 8
mice per condition. ns: not significant.
doi:10.1371/journal.pntd.0001528.g002
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(cfu/organ)of mice infected orallywith strains IP32953 (10
8 cfu), V674 (10
8 cfu) orV674pF1(10
8 and 10
9 cfu). Shown are results fromindividual mice.The
median is indicated by a horizontal line. B: quantification of lesions in Peyer’s patches and spleen of mice infected orally with strains IP32953 (10
8 cfu),
V674 (10
8 cfu) or V674pF1 (10
9 cfu). The limit of detection was 10 cfu per organ. Organs taken at the indicated time were analyzed by histology after
hematoxylin-eosin staining. Tissue lesion scores were recorded and shown are means 6 s.e.m of four mice per condition. *: p#0.05, ns: not significant, {:
dead mice. C: Examples of lesions observed at Day 5 in the spleen and Peyer’s patches from mice inoculated orally with IP32953 or V674pF1 (10
8 cfu).
Arrowheads indicate abscesses, and an N indicate an area of necrosis. In IP32953-infected spleen, hemorrhage is widespread, whereas in V674pF1
infected spleen only subcapsular microhemorrhages (black arrows) and congestioned blood vessels (white arrows) are observed. L: insestinal lumen.
doi:10.1371/journal.pntd.0001528.g003
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not in sera from unvaccinated or V674-vaccinated mice.
Because immunization through the oral route was expected to
induce a mucosal type of immune response, IgA directed against
both F1 and other Yersinia antigens were measured in mucosal
tissues and blood after vaccination with V674pF1. Significant
amounts of IgA were detectable in both intestinal lavages and sera
but not in bronchoalveolar lavages (Fig. 4 C&D). Increasing the
vaccine dose from 10
8 cfu to 10
9 cfu did not significantly affect the
levels of IgA observed.
Cellular immune response to Yersinia antigens elicited by
vaccination
The ability of V674pF1 to induce a cellular immune response
was evaluated by comparing cytokine production by splenocytes
taken from animals vaccinated with V674pF1 or V674 (both at
10
8 cfu) 21 days before, or not vaccinated. Splenocytes were
stimulated with either a Y. pseudotuberculosis antigenic preparation
obtained by sonication, or purified F1 antigen. The mitogen ConA
was used as a positive control (Fig. 5 A&B).
Cells from mice vaccinated with either V674pF1 or V674
significantly produced IFNc in response to Y. pseudotuberculosis
antigens, whereas cells from control naive mice did not (Fig. 5A),
revealing an antigen-specific memory response. Comparable levels
of IFNc for the V674pF1 and V674 groups indicated that the
presence of F1 in V674pF1 did not affect the development of the
cellular response against other Yersinia antigens. Cells from
V674pF1–vaccinated mice also produced IFNc in response to
F1, whereas cells from naive or V674-vaccinated mice did not,
indicating a F1-specific cellular response.
IL-17 production was also examined because IL-17-producing
T lymphocytes (Th17 cells) are key players of antibacterial
Figure 4. Seric and mucosal humoral immune response of vaccinated mice. To determine serum IgG titers against Y. pseudotuberculosis
antigens (A) or against purified F1 antigen (B), blood was taken on day 21 from mice vaccinated orally with either V674 (10
8 cfu; 16 mice) or V674pF1
(32 mice received 10
8 cfu, 8 mice received 10
9 cfu), or from naive animals (8 mice). To determine anti-Y. pseudotuberculosis (C) or anti-F1 (D) IgA levels
in serum, intestine and lungs, groups of 8 mice received 10
8 cfu or 10
9 cfu of strain V674pF1 orally, or were not vaccinated, and were sacrificed 3
weeks later to collect blood, intestinal lavage (5 ml) and bronchoalveolar lavage (2 ml). Each dot represents an individual animal and medians (-) are
shown. *: p,0.05, **: p,0.005, ***: p,0.001, ns: not significant.
doi:10.1371/journal.pntd.0001528.g004
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V674-vaccinated mice produced IL-17 upon stimulation with Y.
pseudotuberculosis antigens (Fig. 5B), whereas cells from naive mice
did not, indicating the recruitment of Y. pseudotuberculosis–specific
IL-17 producing cells. Because splenocytes from only half of the
mice vaccinated with V674pF1 produced IL-17 upon stimulation
by F1, the mean production was not statistically significant.
Notably, Y. pseudotuberculosis antigens induced a stronger produc-
tion of IFNc and IL-17 than F1 (615 and 66 respectively),
indicating that the multiple antigens included are important
targets of cell-mediated immunity.
Protection against pneumonic plague
The ability of V674pF1 to confer protective immunity was
evaluated by challenging immunized mice intranasally with a
lethal dose of the fully virulent Y. pestis CO92 (10
5 cfu=336LD50).
While all unvaccinated animals died within 3–4 days (Fig. 6A), a
single oral inoculation of V674pF1 (10
8 cfu) resulted in complete
(100%) protection. In contrast, vaccination with V674 conferred
protection to 69% of animals only. When a very high challenge
dose of 10
7 cfu CO92 (3,3006LD50) was used to mimic a severe
contamination, mice vaccinated with 10
8 cfu of V674pF1 showed
80% protection and this protection reached 94% when a vaccine
dose of 10
9 cfu was administered (Fig. 6B).
Finally, we evaluated whether the immunity induced by
V674pF1 was protective against a virulent F1-negative Y. pestis.
To this aim, a CO92Dcaf1 Y. pestis was constructed. This mutant
had an LD50 comparable to that of CO92 by the intranasal route
(LD50=5.6610
3 cfu as compared to 2.8610
3 cfu for CO92).
Mice vaccinated orally with 10
9 cfu of V674pF1 completely
resisted a challenge infection (100% survival) by CO92Dcaf at both
the 10
5 cfu infectious dose and the high 10
7 cfu dose (Fig. 6C).
Figure 5. Cellular immune response of vaccinated mice. Splenocytes isolated from mice vaccinated orally 21 days before with strains V674pF1
(10
8 cfu) or V674 (10
8 cfu) or unvaccinated mice (naive) were stimulated in vitro with 5 mg/ml of either a Y. pseudotuberculosis antigenic preparation
(Y. ptb Ag.) or purified F1 antigen. The mitogen Concanavalin A (ConA: 1 mg/ml) served as positive control. Supernatants taken 3 days after
stimulation were tested by ELISA for the presence of IFNc (A) and IL-17 (B). Shown are the mean 6 s.e.m. of 16 mice per condition (2 pooled
experiments). *: p,0.05, **: p,0.005, ***: p,0.001, ns: not significant.
doi:10.1371/journal.pntd.0001528.g005
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Our initial study demonstrated that the naturally attenuated Y.
pseudotuberculosis strain IP32680 could serve as an oral vaccine
against bubonic plague [17]. However, this strain had weaknesses
that precluded its development for human use. Because its genome
had not been analyzed, its naturally low virulence could have
resulted from a point mutation, with the possibility that a reverse
mutation could restore virulence. In addition, IP32680 inoculated
orally conferred only a weak level of protection (30%) against the
pneumonic form of plague [17], after two vaccine doses. The goals
of the present work were therefore twofold: first, to obtain a strain
whose attenuation was irreversible and well characterized, and
second to provide high-level protection against pneumonic plague.
The first objective was reached by using strain IP32953, whose
genome has been sequenced [35], and to attenuate it by deleting
three major virulence genes, thus preventing reversion to
virulence.
The genetically attenuated Y. pseudotuberculosis V674 strain
provided 69% protection against pneumonic plague, and therefore
was clearly more efficient than our previous IP32680 strain.
However, it was still less efficient than attenuated Y. pestis strains
used as plague vaccines in the past such as EV76 [36] or recently
proposed engineered strains [37,38]. Since the pioneer studies of
Meyer, the F1 antigen composing the Y. pestis capsule is recognized
as a major target of protective immunity due to its abundance and
easy access at the bacteria surface [39]. F1 is absent from Y.
pseudotuberculosis, and to enhance the efficiency of V674, the second
step of our work was to introduce the caf operon coding for F1 into
V674. With the presence of F1 at its surface, V674pF1 conferred
full protection (100%) against pneumonic plague. Even against a
very high intranasal challenge dose of CO92 (10
7 cfu, i.e.
3,3006LD50), V674pF1 had an excellent protective score (94%).
V674pF1, after a single oral dose, thus reached a level of
protection that had, to our knowledge, not been reported for other
live vaccines, including attenuated Y. pestis strains [37,40,41] or
recombinant vectors producing Y. pestis antigens such as Salmonella
[11,42] or viruses [12,43].
The F1 capsule is not an essential virulence factor for Y. pestis in
mammals (reviewed by [44]), as shown by the fact that F1-negative
Y. pestis mutants are still mortal for mice, primates and humans
([45,46], the present work) although it is required to achieve full
pathogenicity in certain mouse strains [47]. Y. pestis virulence is
recognized to be multifactorial, so that the transfer of a single gene
in an avirulent Y. pseudotuberculosis was unlikely to increase its
virulence. Indeed, high oral doses of V674pF1 induced no
lethality, in agreement with similar observations in F1-producing
Salmonella candidate vaccines [11].
The live attenuated vaccines have several advantages over
subunit vaccines. Recently developed candidate vaccines against
plague are composed of two antigens: the Y. pestis-specific capsular
F1 antigen and the virulence plasmid-encoded V antigen (LcrV)
common to the three pathogenic Yersinia species. Molecular and
live vaccines based on F1 and V provide protection to mice against
pneumonic plague [12,13,14,16], however they confer only
variable levels of protection to non-human primates [48]. Such
molecular vaccines using Alum as adjuvant mainly induce
antibody production against the F1 antigen [49], allowing virulent
Y. pestis variants lacking the F1 antigen to escape from the
protective immunity of anti-F1 antibodies [46]. In contrast, live
vaccines are strong inducers not only of humoral immunity but
also of cell-mediated immunity [48], an important component of
protection against pneumonic plague [50]. We observed that
splenocytes from mice orally vaccinated with both V674pF1 and
V674 strongly produced IFNc upon restimulation in vitro with Y.
pseudotuberculosis antigens, indicating the development of a Y.
pseudotuberculosis–specific cellular immunity. IFNc typically charac-
terizes the type 1 response critical for optimal vaccine-induced
protection against Y. pestis infection. Indeed, it was previously
shown that injection of IFNc and TNFa protects mice against Y.
pestis infection [51] and that neutralization of these cytokines
Figure 6. Protection of vaccinated mice against pneumonic
plague. Mice having received a single oral vaccination with strains
V674pF1 or V674 at the indicated doses were challenged 4 weeks later
by intranasal instillation of the indicated dose of Y. pestis CO92 (A, B) or
CO92Dcaf (C). Mouse survival was recorded daily for 21 days. Results
from repeated experiments with 7–8 animals per group were pooled
and the total number of mice per condition is indicated inside the
corresponding bar. *: p#0.05, **: p#0.005, ***: p,0.001. ns: not
significant.
doi:10.1371/journal.pntd.0001528.g006
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[52]. IFNc activates phagocytes and help them destroy internal-
ized bacteria. Therefore the potent IFNc production by
splenocytes from vaccinated mice observed in the present work
may have such a role. The recruitment of Yersinia-specific cells
producing IL-17 (Th17) was also observed. There is growing
evidence that the development of Th17 cells is critical to vaccine-
induced protection against mucosal infections by pathogenic
bacteria, parasites, viruses and fungi [31,53]. Indeed, IL-17 is a
powerful inducer of PMN recruitment and release of antimicrobial
peptides, and contributes to immunity induced against pneumonic
plague by an attenuated Y. pestis candidate vaccine [34]. Because
such effector Th17 cells can collaborate with Th1 lymphocytes
[53], the induction of both subsets by V674pF1 may be a key of
the high protection observed against Y. pestis in the lungs.
It is most notable that vaccination using the live attenuated
V674pF1 Y. pseudotuberculosis strain provided full protection against
pneumonic plague caused by a virulent Y. pestis strains lacking the
F1 antigen, whereas the live attenuated Y. pestis KIM D27 (Dpgm),
used as vaccine in other studies, failed to protect [46,49]. This
inability of a live Y. pestis to protect was interpreted as resulting
from a focalization of the immune response against the abundant
F1 covering the bacteria, to the detriment of other antigens [49].
On the contrary, we show here that V674pF1 was able to trigger
immunity simultaneously against F1 and the large array of target
antigens common to Y. pestis and Y. pseudotuberculosis,a s
demonstrated by the comparable IgG titers against these antigens
observed after vaccination with vaccine strains producing F1 or
not. Moreover, the cellular response against Yersinia antigens was
not only comparable after vaccination with V674 or V674pF1, but
was also much stronger than that induced by the F1 antigen. This
absence of focalization of the immune response on F1 thereby
greatly enhances the likelihood of protection against a wide
spectrum of Y. pestis variants. The contrast with studies using KIM
D27 as vaccine [46,49] cannot be ascribed to a difference in the
amount of F1 capsule because V674pF1 produces as much F1 as
Y. pestis. It could rather result from yet unidentified differences of
immunogenicity between the two Yersinia species, or on the
different routes of vaccination (intramuscular versus oral). In this
regard, the F1 capsule also did not alter the capacity of the Y.
pseudotuberculosis strain to settle in the intestinal tract. This was
however not surprising because Y. pestis is virulent by the oral
route, as shown by human plague cases after eating meat from an
infected animal [54]. That V674pF1 was efficient through the oral
route was an additional advantage because oral vaccination is both
convenient, well accepted by persons, and avoids the risk of
contamination through used syringes during mass vaccination.
In previous studies of mouse vaccination with F1-V subunit
vaccines, repeated injections were required to obtain full
protection [14,16]. In contrast, full protection against pneumonic
plague was obtained in the present work after vaccination with a
single oral dose of V674pF1. The capacity of live vaccines to
stimulate immunity for an extended period of time was the likely
key to this efficiency. V674pF1 given by the oral route persisted for
weeks in the gut, allowing a prolonged antigen presentation to the
immune system.
F1 production significantly improved the performance of
V674pF1 compared to V674, consistent with the development of
F1-targeted effector mechanisms efficient in the lungs. The
production of high amounts of IgG and IgA indicated that the
humoral immune response was triggered at both systemic and
mucosal levels. Antibodies contribute to defense against pneu-
monic plague, as shown by previous studies in which non-immune
or immunodeficient mice were protected by instillation of anti-F1
antibodies in the airways [55,56,57]. Seric IgG have an easy access
to the highly vascularized lung tissues and those induced by
V674pF1 may have played such a role. Because immunization
started at a mucosal surface, IgA could also have been actors of
V674pF1-induced lung immunity [58]. No IgA could however be
detected in bronchoalveolar lavages, showing that IgA were not
necessary to protection.
In summary, this study demonstrated that a high level
protection against pneumonic plague can be obtained by a single
oral vaccination with the live attenuated Y. pseudotuberculosis
V674pF1 producing the Y. pestis F1 capsule. Because the strain
has been irreversibly attenuated by deletion of essential virulence
factors, it colonizes the intestinal tract without causing lesions and
stimulates both humoral and cell-mediated anti-plague immunity.
Easy to administrate orally and costless to produce, this candidate
vaccine is therefore well adapted to mass vaccination in endemic
tropical regions, offering promising perspectives to control
pneumonic plague mortality and transmission.
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